Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
News
|
Comment
|
Features
|
Analysis
|
Supplements & Reports
|
People
|
Events
|
Multimedia
|
Science Abstracts
|
Scrip   
CHMP recommends guidance to manage risk of PML with Biogen's Tysabri
22 January 2010
Katie McQue

The EU's CHMP has recommended additional measures to be taken to mitigate the risk developing progressive multifocal leucoencephalopathy (PML) in patients with relapsing-remitting multiple sclerosis who are receiving treatment with Biogen Idec/ Elan's Tysabri (natalizumab).

PML...



Please Login to read the full article.
 
Not a subscriber? Request a FREE Trial Subscribe to Scrip
RELATED CONTENT
NEWS Scrip News Other Informa News
ANALYSIS Scrip Analysis Other Informa Analysis
COMMENT Scrip Comment Other Informa Comment
FEATURES Scrip Features Other Informa Features
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm